HALO Shariah Compliance
Screening Methodology: AAOIFI
LOCKED
Halozyme Therapeutics Inc. Stock Analysis HALO
United States Health Care Mid Cap Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. The company markets and sells Hylenex recombinant, which is a formulation of rHuPH20. The company markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Read More HALO Chart
Halozyme Therapeutics Inc vs S&P 500 Comparative Returns
Analysis of HALO stock performance compared to the broader market (S&P 500) across multiple timeframes.
YTD Performance
- Halozyme Therap... (HAL...) 41.66%
- S&P 500 -4.27%
Halozyme Therap... Outperformed S&P 500 by 45.93%
1Y Performance
- Halozyme Therap... (HAL...) 61.22%
- S&P 500 8.86%
Halozyme Therap... Outperformed S&P 500 by 52.36%
3Y Performance
- Halozyme Therap... (HAL...) 81.34%
- S&P 500 37.21%
Halozyme Therap... Outperformed S&P 500 by 44.13%
5Y Performance
- Halozyme Therap... (HAL...) 186.87%
- S&P 500 92.3%
Halozyme Therap... Outperformed S&P 500 by 94.57%
Key Statistics
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$68.11Volume
5.15MP/E Ratio (TTM)
16.3652 Week Range
Market Cap
7.91BAvg. Volume
1.98MDividend Yield
-Financial Metrics & Statements
- Per Share Data
- Ratios
- Statements
| Currency: USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Revenue per Share (TTM) | 1.98 | 3.22 | 4.88 | 6.54 | - |
EBIT per Share (TTM) | 1.07 | 2.01 | 2.14 | 2.68 | - |
Earnings per Share (EPS) (TTM) | 0.95 | 2.86 | 1.48 | 2.13 | - |
EPS Forward | - | 2.74 | 1.44 | 2.1 | - |
Super Investors
Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.
Joel Greenblatt
% Portfolio:
0.02 Recent Activity:9.66%
Ken Fisher
% Portfolio:
< 0.01 Recent Activity:28.00%
Jefferies Group
% Portfolio:
0 Recent Activity:-100.00%
FAQ's
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.
Alternate Halal Stocks
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
